Scleroderma in Children and Adolescents: Localized Scleroderma and Systemic Sclerosis

Area of Science:

• Rheumatology
• Pediatric Autoimmune Diseases
• Dermatology

Background:

• Scleroderma encompasses two primary forms: localized scleroderma (LS) and systemic sclerosis (SSc).
• Both subtypes are chronic conditions that can manifest in various patterns and affect extracutaneous sites in children.
• Juvenile systemic sclerosis (SSc) carries a significant risk of life-threatening organ fibrosis and vasculopathy, while juvenile localized scleroderma (LS) can lead to disfigurement and functional impairment.

Purpose of the Study:

• To summarize the key aspects of pediatric scleroderma, including its forms, complications, and management.
• To highlight the differential impact of localized scleroderma versus systemic sclerosis on pediatric patients.
• To emphasize the importance of early diagnosis and targeted treatment in improving outcomes for children with scleroderma.

Main Methods:

• Review of existing literature on pediatric scleroderma.
• Analysis of disease presentation, subtypes, and extracutaneous manifestations.
• Summary of current treatment strategies and prognostic factors.

Main Results:

• Juvenile SSc presents a higher risk of mortality and severe visceral organ involvement (lung, heart, fibrosis, vasculopathy).
• Juvenile LS, while rarely fatal, commonly results in significant morbidity, including disfigurement and functional deficits.
• Treatment focuses on inflammation control and management of specific complications.

Conclusions:

• Scleroderma in children requires careful management tailored to its specific form (LS or SSc).
• Prompt diagnosis and intervention are critical for mitigating morbidity and improving long-term outcomes in pediatric scleroderma patients.
• Understanding the distinct risks associated with juvenile LS and SSc is essential for effective patient care.